Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti‐inflammatory drug‐related peptic ulcers in Japanese patients

Summary Background The use of proton pump inhibitors for prevention of nonsteroidal anti‐inflammatory drug ( NSAID )‐induced gastrointestinal adverse events is well documented. However, data regarding the efficacy and safety of this approach in J apan are scarce. Aim To evaluate the efficacy and tolerability of esomeprazole in preventing NSAID ‐induced peptic ulcers in J apanese at‐risk patients. Methods Male and female J apanese adult patients (aged ≥20 years) with endoscopically confirmed history of peptic ulcers who required long‐term oral NSAID therapy for a chronic inflammatory condition were randomised to 24 weeks' treatment with esomeprazole 20 mg once daily or matching placebo. The primary end point was the K aplan– M eier estimated proportion of ulcer‐free patients. Results Overall, 343 patients were randomised to treatment (esomeprazole, n = 175; placebo, n = 168). The K aplan– M eier estimated ulcer‐free rate over the 24‐week treatment period was significantly higher (log‐rank P < 0.001) in esomeprazole‐treated patients (96.0%; 95% CI 92.8, 99.1) than in placebo recipients (64.4%; 95% CI 56.8, 71.9). Esomeprazole was effective at preventing peptic ulcers in both H elicobacter pylori ‐positive and ‐negative patients (96.3% vs. 95.5% of patients ulcer‐free, respectively); however, in the placebo group, the proportion of ulcer‐free patients at 24 weeks was markedly lower among H . pylori ‐positive than ‐negative patients (59.7% vs. 69.9%). The NSAID type did not seem to affect the estimated ulcer‐free rate with esomeprazole. Treatment with esomeprazole was well tolerated. Conclusion Esomeprazole 20 mg once daily is effective and safe in preventing ulcer recurrence in J apanese patients with a definite history of peptic ulcers who were taking an NSAID ( ClinicalTrials.gov identifier: NCT 00542789).